Citigroup analyst John Deakin-Bell upgrades ResMed (NYSE:RMD) from Neutral to Buy.
Where Stanley Black & Decker Stands With Analysts
Stanley Black & Decker (NYSE:SWK) has observed the following analyst ratings within the last quarter:
Citigroup Upgrades ResMed to Buy
Citigroup analyst John Deakin-Bell upgrades ResMed (NYSE:RMD) from Neutral to Buy.
Related Posts
Solana Plummets 14% On Heels Of Spot Bitcoin ETF Delay, $640M Liquidation Cascade
Fears of a delay in Spot Bitcoin ETF approvals spurred the biggest cryptocurrency market dip in months.
Camping World Holdings Q2 EPS $2.16 Beats $1.98 Estimate, Sales $2.17B Beat $2.04B Estimate
Camping World Holdings (NYSE:CWH) reported quarterly earnings of $2.16 per share which beat the analyst consensus estimate of $1.98 by 9.09 percent. This is a 13.94 percent decrease over earnings of $2.51 per share from
Renault-Nissan-Mitsubishi Alliance Lists New Initiatives To Ramp-Up Partnership
Renault-Nissan-Mitsubishi Alliance has proposed new initiatives following the approval of Renault ADR (OTC:RNLSY) and Nissan Motor Co Ltd (OTC:NSANY) Boards. The alliance will have…